Secretome Therapeutics, a developer of investigational nCPC-based cell and cell-derived therapies for cardiac repair, has raised $30 million in Series A funding led by RA Capital Management. The company targets improvements in ventricular function and reduced fibrosis for patients with orphan cardiac diseases including Duchenne muscular dystrophy-associated cardiomyopathy. The capital will advance STM-01, its lead neonatal cardiac progenitor cell therapy, into further clinical development.
Cardiac Cell Therapy Momentum Builds
The timing comes amid accelerating validation in the space. Capricor Therapeutics reported Phase 3 data showing 54% slowing of upper limb deterioration for its cell therapy in DMD, with an FDA PDUFA date set for August 2026. Secretome's approach using neonatal cardiac progenitor cells addresses a similar high-unmet-need indication through a cell-free secretome platform.
High Unmet Need in Orphan Cardiomyopathies
Duchenne muscular dystrophy patients face severe cardiac complications with limited treatment options. Current solutions fall short due to challenges in scalable manufacturing and immunogenicity risks associated with whole-cell approaches. Secretome's focus on nCPC-derived exosomes and secretomes aims to overcome these barriers.
Neonatal Progenitor Cells Offer Differentiation
Secretome built STM-01 from neonatal cardiac progenitor cells isolated during newborn open-heart surgery. Preclinical data in peer-reviewed publications demonstrate superior cardiac repair versus adult cells. This differs from competitors pursuing adult mesenchymal stem cells or gene therapies.
"We believe STM-01 will be a disease-modifying and best-in-class cellular therapy." - Matthew Hammond
Sole Tier-1 Investor Signals Conviction
RA Capital Management committed the entire $30 million round as sole investor. The firm's portfolio includes Solid Biosciences and Tenaya Therapeutics, showing deep expertise in Duchenne and cardiology. David Lubner joined the board following the round.
Stem Cell Therapy Market Scales Rapidly
The stem cell therapy market is projected to grow from $613.7 million in 2025 to $5.84 billion by 2035 at a 25.26% CAGR. Key trends include the shift toward allogeneic and secretome-based therapies that enable scalable production for rare indications like DMD cardiomyopathy.
Secretome's manufacturing partnership with RoosterBio for large-scale bioreactor production positions it to capitalize on this expansion.